

00 052051

(3-methyl-TTNCB)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 1

RECEPTOR
pRShRAR-alpha (wt)
pRShRAR-beta (wt)
pRShRAR-gamma (wt)
pRShRXR-alpha (wt)
pRSmRXR-beta (wt)
pRSmRXR-gamma (wt)

(ALL TRANS RETINOIC ACID)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 2

RECEPTOR

- pRSR_hRAR-alpha (wt)
- + pRSR_hRAR-beta (wt)
- ★ pRSR_hRAR-gamma (wt)
- pRSR_mRXR-alpha (wt)
- ✖ pRSR_mRXR-beta (wt)
- pRSR_mRXR-gamma (wt)

(9CIS RETINOIC ACID)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 3

RECEPTOR
— pRShRAR-alpha (wt)
—+ pRShRAR-beta (wt)
—* pRShRAR-gamma (wt)
—o pRShRXR-alpha (wt)
—x pRSmRXR-beta (wt)
—□ pRSmRXR-gamma (wt)

(3-methyl-TTNEB)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 4

- pRShRAR-alpha (wt)
- pRShRAR-beta (wt)
- pRShRAR-gamma (wt)
- pRShRXR-alpha (wt)
- pRSmRXR-beta (wt)
- pRSmRXR-gamma (wt)

(3-bromo-TTNEB)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 5

- pRShRAR-alpha (wt)
- + pRShRAR-beta (wt)
- * pRShRAR-gamma (wt)
- o pRShRXR-alpha (wt)
- x pRSmRXR-beta (wt)
- pRSmRXR-gamma (wt)

08 052051

(3-methyl-TTNCHBP)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 6

- pRSbRAR-alpha (wt)
- pRSbRAR-beta (wt)
- pRSbRAR-gamma (wt)
- pRSbRXR-alpha (wt)
- pRSbRXR-beta (wt)
- pRSbRXR-gamma (wt)
- pRSmRXR-alpha (wt)
- pRSmRXR-beta (wt)
- pRSmRXR-gamma (wt)

(3-methyl-TTNEHBP)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 7

- pRShRAR-alpha (wt)
- ↑ pRShRAR-beta (wt)
- * pRShRAR-gamma (wt)
- pRShRXR-alpha (wt)
- ✖ pRShRXR-beta (wt)
- pRSmRXR-gamma (wt)

08 052051




Fig. 8




Fig. 9

EFFECT OF RETINOID ON RAT HDL CHOLESTEROL




Figure 10

00 052051




Figure 11

Myeloma RPMI-8226 Cell Proliferation




Figure 12